NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india) arrow 12346.10 -9.40 -0.08%
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Jagsonpal Pharmaceuticals Limited (NSE: JAGSNPHARM)

 
JAGSNPHARM Technical Analysis
4
As on 17th Jan 2020 JAGSNPHARM Share Price closed @ 27.80 and we RECOMMEND Buy for LONG-TERM with Stoploss of 25.75 & Strong Buy for SHORT-TERM with Stoploss of 26.10 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

JAGSNPHARM Share Price

Open 27.50 Change Price %
High 28.75 1 Day -0.50 -1.77
Low 27.25 1 Week 0.95 3.54
Close 27.80 1 Month 0.50 1.83
Volume 15163 1 Year -3.30 -10.61
52 Week High 32.70 | 52 Week Low 20.20
 
NSE INDIA Most Active Stocks
IDEA 4.50 -25.00%
YESBANK 39.25 -1.75%
BHARTIARTL 500.05 5.52%
SBIN 318.00 -1.64%
DISHTV 13.10 2.75%
IDFCFIRSTB 43.50 -3.33%
INFRATEL 218.25 -10.20%
JPASSOCIAT 2.20 4.76%
SUZLON 2.50 -3.85%
SAIL 50.95 0.20%
 
NSE INDIA Top Gainers Stocks
VISESHINFO 0.10 100.00%
SCAPDVR 0.20 33.33%
DPWIRES 88.80 20.00%
DSSL 29.70 20.00%
SALONA 73.35 19.95%
HINDCOMPOS 239.35 19.14%
LYPSAGEMS 5.30 19.10%
ALPA 21.95 17.38%
SPYL 0.35 16.67%
JOCIL 127.50 14.56%
 
NSE INDIA Top Losers Stocks
UVSL 0.10 -33.33%
IDEA 4.50 -25.00%
SPENTEX 0.30 -14.29%
JIKIND 0.30 -14.29%
NTL 0.35 -12.50%
NTL 0.35 -12.50%
GTLINFRA 0.40 -11.11%
VIJIFIN 0.40 -11.11%
INFRATEL 218.25 -10.20%
PSL 0.45 -10.00%
 
 
JAGSNPHARM
Daily Charts
JAGSNPHARM
Intraday Charts
Whats New @
Bazaartrend
JAGSNPHARM
Free Analysis
 
JAGSNPHARM Important Levels Intraday
RESISTANCE30.69
RESISTANCE29.76
RESISTANCE29.19
RESISTANCE28.62
SUPPORT26.98
SUPPORT26.41
SUPPORT25.84
SUPPORT24.91
 
JAGSNPHARM Target for Month January
4th UP TARGET35.62
3rd UP TARGET32.44
2nd UP TARGET30.47
1st UP TARGET28.51
1st DOWN TARGET22.89
2nd DOWN TARGET20.93
3rd DOWN TARGET18.96
4th DOWN TARGET15.78
 
JAGSNPHARM Weekly Target
4th UP TARGET33.98
3rd UP TARGET31.69
2nd UP TARGET30.28
1st UP TARGET28.87
1st DOWN TARGET24.83
2nd DOWN TARGET23.42
3rd DOWN TARGET22.01
4th DOWN TARGET19.72
 
JAGSNPHARM Target for Year 2020
4th UP TARGET49.79
3rd UP TARGET42.06
2nd UP TARGET37.29
1st UP TARGET32.51
1st DOWN TARGET18.89
2nd DOWN TARGET14.11
3rd DOWN TARGET9.34
4th DOWN TARGET1.61
 
Jagsonpal Pharmaceuticals Limited ( NSE INDIA Symbol : JAGSNPHARM )
Sector : Pharmaceuticals - Formulations And Other Stocks in Same Sector
 
JAGSNPHARM Synopsis Technicals View
50 Day EMA Close is Above EMA 50 (Short Term)
Bullish
100 Day EMA Close is Above EMA 100 (Mid Term) Bullish
200 Day EMA Close is Above EMA 200 (Long Term) Bullish
MACD (12 26 9) MACD Line is Grater Then SIGNAL Line Bullish
RSI (14) RSI is 67.61 Sideways
MFI (14) MFI is 76.53 Sideways
CCI (20) CCI is Above 100 Over Bought
WILLIAM %R (14) William %R is Above -20 Over Bought
ADX (14) ADX is Above 20 & +DI is Above -DI Up Trend
PSAR Stoploss For Long Buy 25.58
10 Day Avg Volume Traded -31.48 % Less then 10 Day Average Volume
 
JAGSNPHARM Other Details
Segment EQ
Market Capital 0.00
Sector Pharmaceuticals - Formulations
Industry
Offical website
 
JAGSNPHARM Address
JAGSNPHARM
N/A
 
JAGSNPHARM Latest News
 
Your Comments and Response on Jagsonpal Pharmaceuticals Limited
 
JAGSNPHARM Business Profile
Jagson Pharma is in the Pharmaceuticals - Formulations sector. Jagsonpal Pharmaceuticals (JAGSONPH) is a pharmaceutical company producing drugs and formulations. The company was incorporated in 1978 as a private limited company and went public in 1986. The company specializes in developing and manufacturing bulk drugs and pharmaceutical formulations. It focuses on several therapeutic groups like anti-arthritics, anti-inflammatories, analgesics, anti-spasmodics, progesterones, anabolic steroids, anesthetics and anti-fungals. Top selling brands include Lycored, Maintane, Metadec, Metabol, Doxypal DR, Parvon, and Indocap SR. The company manufactures active pharmaceutical ingredients (APIs) like Allylestrenol, Disulfiram, Tolnaftate, ..etc. The bulk drug range includes dextropropoxyphene HCl, tolnaftate, dextropropoxyphene napsylate and thiopental sodium. The manufacturing facility in Delhi is WHO and GMP-certified for the production of various dosage forms and bulk drugs and intermediates. The company also maintains a number of dedicated contract manufacturing facilities around the globe. It has an expanding international portfolio of affiliates, joint ventures and representative offices across the globe. The distribution network in India is comprised of over 1,500 authorized stockists who are serviced by depots. The products are retailed at over 125,000 pharmacies. The company is represented by 2,500 agents worldwide and has offices in three continents. The company`s operations span Russia, USA, Brazil, Ukraine, Sri Lanka, Cameroon, Argentina, Thailand, Germany, Switzerland, Korea, Egypt and Vietnam. The company has a sales office in New York through which it services North and Latin American clients and in Belarus, it has an operation center with a sales and distribution team. The current market capitalisation stands at Rs 23.71 crore.The company has reported a standalone sales of Rs 36.79 crore and a Net Profit of Rs 0.01 crore for the quarter ended Sep 2013. The company management includes R P S Kochhar - Chairman & Managing Director, S K Goyal - Director, Govind Deo - Additional Director, Bharat Sinh - Additional Director, Ishpal Singh Ghai - Additional Director. It is listed on the BSE with a BSE Code of 507789 and the NSE with an NSE Code of JAGSNPHARM. Its Registered office is at T-210 J, Shahpur Jat , New Delhi,Delhi - 110049.
 
2005-2019 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service